Recent Finacing
Recent Raise
Selva Therapeutics develops SLV213, an oral small-molecule cathepsin L inhibitor that blocks viral entry, showing broad preclinical activity against SARS‑CoV‑2, SARS, Ebola, and Nipah and completed IND‑enabling safety studies.